CN105687438A - Method for preparing traditional Chinese medicine composition for treating prostatitis - Google Patents
Method for preparing traditional Chinese medicine composition for treating prostatitis Download PDFInfo
- Publication number
- CN105687438A CN105687438A CN201610149899.2A CN201610149899A CN105687438A CN 105687438 A CN105687438 A CN 105687438A CN 201610149899 A CN201610149899 A CN 201610149899A CN 105687438 A CN105687438 A CN 105687438A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- traditional chinese
- semen
- prostatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 14
- 201000007094 prostatitis Diseases 0.000 title abstract description 16
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241000446281 Eschenbachia blinii Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 240000005175 Turpinia pomifera Species 0.000 claims description 9
- 239000004575 stone Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 12
- 210000002307 prostate Anatomy 0.000 abstract description 11
- 230000001684 chronic effect Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 241000567398 Dischidia chinensis Species 0.000 abstract 1
- 241000237858 Gastropoda Species 0.000 abstract 1
- 244000196929 Oenothera glazioviana Species 0.000 abstract 1
- 241000124033 Salix Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000284 extract Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000007560 sedimentation technique Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001633583 Adenophora Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000731466 Chlorostoma Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001671215 Staphyleaceae Species 0.000 description 1
- 241000237983 Trochidae Species 0.000 description 1
- 241001436151 Turpinia arguta Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a method for preparing a traditional Chinese medicine composition for treating prostatitis, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by taking radix adenophorae, semen brassicae, herb of dischidia chinensis Champ.ex Benth., black fovea snails, roots of oenothera erythrosepala Borb., folium turpiniae, herb of conyza blinii Levl. and willow leaves as raw materials. The traditional Chinese medicine composition prepared through the method achieves the treatment effect on chronic abacterial prostatitis by lowering the level of TNF-alpha and IL-8 in the patient prostate tissue and reduces the inflammatory reaction degree to promote repairing of the prostate tissue structure.
Description
The application be applicant Shandong Weikang Biomedical Science and Technology Co., Ltd. propose application for a patent for invention (denomination of invention is: one treats prostatitic Chinese medicine composition and application thereof, application number is: 2014104612187, and the applying date is: on JIUYUE 12nd, 2014) divisional application。
Technical field
The invention belongs to technical field of Chinese medicine, relate to a kind of method prepared and treat prostatitic Chinese medicine composition。
Background technology
Chronic nonbacterial prostatitis is a kind of common male urinary surgical diseases, and main manifestations is pelvis area pain, it is seen that in perineum, penis, crissum portion, urethra, pubis portion and lumbosacral region position。Paruria can behave as urgent micturition, frequent micturition, dysurea and nocturia and increases。Due to chronic pain obstinate, patients ' life quality declines, and is likely to the symptom of sexual disorders, anxiety, depression, insomnia, hypomnesis。Multiplex antibiotic, analgesic are treated clinically at present, but antibiotic, analgesic have certain side effect, and therapeutic process patient is very painful。
Treatment of chronic prostatitis is had advantage by motherland's medical science。The methods such as classical method mainly includes oral medicinal herb, external sticks, herbal enema and suppository rectally, making a general survey of current treatment thoughts and method, with blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis is treating stranguria, the kidney invigorating etc. is generally used in the treatment of clinical chronic prostatitis for therapeutic rules。Further, Chinese medicine prostatitis, there is the advantages such as cheap and easy to get, untoward reaction is little, therefore become current study hotspot and one of trend。
Summary of the invention
Modern medicine is thought, the pathogenesis of chronic nonbacterial prostatitis is relevant to the factor such as urine reflux, cytokine mediated immunoreation in prostatic special anatomical structure, Posterior urethral smooth muscle spasm, prostate, and wherein Cytokine is further notable。The present inventor on the basis that cytokine is theoretical, the method using motherland's medical science, have found the new method of a treatment chronic nonbacterial prostatitis。Based on this Therapeutic Method, it is an object of the invention to provide the Chinese medicine composition of a kind of resistance prostatitis and application thereof。
In order to realize the purpose of the present invention, inventor is studied by lot of experiments and persistent exploration, is finally obtained following technical scheme:
One treats prostatitic Chinese medicine composition, including Chinese medicine extract and pharmaceutic adjuvant, described Chinese medicine extract is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 9-15 part, Semen Sinapis Albae 9-15 part, stone Semen Benincasae 17-24 part, sea Semen Cassiae 10-18 part, Radix Oenotherae erythrosepalae 20-30 part, leaf of Turpinia pomifera (Roxb) D O. 20-30 part, conyza blinii 9-15 part, Folium Salicis Babylonicae 6-10 part。
Preferably, treating prostatitic Chinese medicine composition as mentioned above, described Chinese medicine extract is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 11-13 part, Semen Sinapis Albae 11-13 part, stone Semen Benincasae 19-21 part, sea Semen Cassiae 13-15 part, Radix Oenotherae erythrosepalae 23-26 part, leaf of Turpinia pomifera (Roxb) D O. 23-26 part, conyza blinii 11-13 part, Folium Salicis Babylonicae 7-9 part。
In a most preferred embodiment of the present invention, Chinese medicine extract as above is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 12 parts, Semen Sinapis Albae 12 parts, 20 parts of stone Semen Benincasae, sea Semen Cassiae 14 parts, Radix Oenotherae erythrosepalae 25 parts, leaf of Turpinia pomifera (Roxb) D O. 25 parts, conyza blinii 12 parts, Folium Salicis Babylonicae 8 parts。
Preferably, the prostatitic Chinese medicine composition of above-mentioned treatment is oral formulations。Further preferably, described oral formulations includes oral liquid, granule, tablet and capsule。
By the preparation method of the compound granule that above-mentioned each Chinese crude drug preparation cost is invented, comprise the steps: to weigh the Radix Adenophorae 9-15 part cleaned up, Semen Sinapis Albae 9-15 part, stone Semen Benincasae 17-24 part, sea Semen Cassiae 10-18 part, Radix Oenotherae erythrosepalae 20-30 part, leaf of Turpinia pomifera (Roxb) D O. 20-30 part, conyza blinii 9-15 part, Folium Salicis Babylonicae 6-10 part, merge, boiling twice, collecting decoction, it is evaporated to extractum, adding ethanol makes alcohol content reach 70-80% (v/v), stirring, stand, filter, filtrate reduced in volume becomes relative density during to 65 DEG C to be 1.20-1.30, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, pulverized 80 mesh sieves, obtain clear paste powder；Clear paste powder is put in trough type mixing machine together with pharmaceutically acceptable adjuvant, stirring, it is slowly added into binding agent while stirring, to making soft material, granulates with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, take out, cool and obtain granule。
It should be noted that what the Chinese medicine composition of the present invention adopted in preparation process traditional Chinese medicinal material raw materials source is as follows: Radix Adenophorae selects Campanulaceae adenophora tetraphyllaAdenophoratetraphylla(Thunb.) Fisch.Dry root。Semen Sinapis Albae selects crucifer Caulis et Folium Sinapis albeeSinapisalbaL.Dry seed。Trailing plants section eye tree nelumbium eye tree lotus selected by stone Semen BenincasaeDischidiachinensisChamp.exBenth.Dry herb。Sea Semen Cassiae selects Trochidae animal Chlorostoma nigerrima (Gmelin)Chlorostomanigerrinma(Gmelin)Shell。Radix Oenotherae erythrosepalae selects Oenotheraceae Radix Oenotherae erythrosepalaeOenotheraerythrosepalaBorbDry root。Leaf of Turpinia pomifera (Roxb) D O. selects Staphyleaceae plant sharp point Turpinia pomifera(Roxb) D O.Turpiniaarguta(Lindl.) Seem. ［ OchrantheargutaLindl. ］Dried leaves。Conyza blinii selects the dry herb of the false fluffy platymiscium little Herba Acroptili repentis ConyzabliniiLevl. of Compositae。Folium Salicis Babylonicae selects Salicaceous Plants Salix babylonica L.SalixbabylonicaL.Dried leaves。
The secretion of cytokine is the key factor that tissue is inflamed, and TNF-α and IL-8 proinflammatory gene representation play very important effect in the immunomodulating of body and the pathogenic process of chronic nonbacterial prostatitis。Inflammation can produce TNF-α under the effects such as infection, toxin, wound, these cytokines can increase the expression of chemotactic factor such as IL-8, body tissue is caused damage by respective mechanism and causes pain by expression product, and regulation and control inflammatory factor can suppress inflammatory reaction indirectly。Therefore the present inventor selects TNF-α in prostata tissue, IL-8 level as the comparison index that chronic nonbacterial prostatitis rat is treated, found that: compared with sham operated rats, in model control group rat prostate tissue TNF-α and IL-8 level increase (P< 0.01)；Compared with model control group, adopt TNF-α and IL-8 level in the treatment group rat prostate tissue of Chinese medicine extract intervention of the present invention significantly reduce (P< 0.01)。Therefore, present invention also offers a kind of pharmaceutical applications, it may be assumed that the application in the medicine of preparation treatment chronic nonbacterial prostatitis of the above-mentioned Chinese medicine extract。
Compared with prior art, the Chinese medicine composition of the present invention plays the therapeutical effect to chronic nonbacterial prostatitis by reducing TNF-α and IL-8 level in patient's prostata tissue, reduces inflammatory reaction degree, thus promoting the reparation of prostata tissue structure。
Detailed description of the invention
The following is the preparation embodiment of Chinese medicine composition of the present invention and test of pesticide effectiveness example, technical scheme is done and is described further, but protection scope of the present invention is not limited to these embodiments。
The preparation of embodiment 1 granule
Get the raw materials ready: Radix Adenophorae 1.2kg, Semen Sinapis Albae 1.2kg, stone Semen Benincasae 2.0kg, sea Semen Cassiae 1.4kg, Radix Oenotherae erythrosepalae 2.5kg, leaf of Turpinia pomifera (Roxb) D O. 2.5kg, conyza blinii 1.2kg, Folium Salicis Babylonicae 0.8kg。
Preparation: weigh the above-mentioned Chinese crude drug cleaned up by recipe quantity, merge, pulverize, boiling twice, add water 10 times amount into medical material weight for the first time, decoct 2h, add water 8 times amount into medical material weight for the second time, decoct 1h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 it is evaporated at 65 DEG C of temperature, (v/v) ethanol makes alcohol content reach 75% (v/v) to add 95%, stirring, stand 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, dried object pulverized 80 mesh sieves, obtain clear paste powder；Weigh clear paste powder 10g, lactose 80g, microcrystalline Cellulose 80g, sodium carboxymethyl cellulose 15g, put in trough type mixing machine, stir 20 minutes, be slowly added into 55% ethanol (volumetric concentration is the ethanol water of 55%) while stirring, to making soft material, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, take out, cool and obtain granule, packing by every bag of 10g。
The preparation of embodiment 2 granule
Get the raw materials ready: Radix Adenophorae 1.5kg, Semen Sinapis Albae 1.2kg, stone Semen Benincasae 1.8kg, sea Semen Cassiae 1.8kg, Radix Oenotherae erythrosepalae 2.0kg, leaf of Turpinia pomifera (Roxb) D O. 3.0kg, conyza blinii 1.0kg, Folium Salicis Babylonicae 1.0kg。
Preparation: weigh the above-mentioned traditional Chinese medicinal material raw materials cleaned up by recipe quantity, merge, pulverize, boiling twice, add water 10 times amount into medical material weight for the first time, decoct 2h, add water 8 times amount into medical material weight for the second time, decoct 1h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 it is evaporated at 65 DEG C, (v/v) ethanol makes alcohol content reach 75% (v/v) to add 95%, stirring, stand 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, pulverized 80 mesh sieves, obtain clear paste powder；Weigh clear paste powder 10g, lactose 80g, microcrystalline Cellulose 80g, sodium carboxymethyl cellulose 15g, put in trough type mixing machine, stir 20 minutes, be slowly added into 55% ethanol (volumetric concentration is the ethanol water of 55%) while stirring, to making soft material, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, take out, cool and obtain granule, packing by every bag of 10g。
The clinical trial of chronic nonbacterial prostatitis rat model is studied by embodiment 3 Chinese medicine granules
Only, initial weight 210-250g, ad lib, drinking-water also keep 12h light and shade alternate illumination to 2 month female SD rat 6O, indoor temperature 18～25 DEG C, humidity 45%-65%, well-ventilated, adapt to 1 week at this feeding environment before experiment。Random digits table is adopted to be divided into model control group, treatment group and each 2O of sham operated rats only。After taking lumbar injection 10% chloral hydrate anesthesia rat, in hypogastric region median incision under aseptic condition, expose both sides seminal vesicle and prostate, rats in sham-operated group is in lateral lobe of prostate gland injecting normal saline 0.2mL/ only, all the other rats are injected to lateral lobe of prostate gland respectively with 25% XIAOZHILING ZHUSHEYE 0.2mL, close abdomen。Chronic nonbacterial prostatitis model can be formed after 5 weeks。Pathological change is inflammatory cell infiltration in body of gland, and secretions reduces, and lumen of gland blocks, reduces, interstitial fibrosis。Postoperative 5th day each group of tested material starting the following dosage of correspondingly gavage: model control group is normal saline 10mL/kg；Sham operated rats is normal saline 10mL/kg；The clear paste powder 0.75g/kg(clear paste powder that treatment group is embodiment 1 preparation is dissolved in normal saline)。Each group is all administered by 1 time/d, totally 5 weeks。
After last administration 60min, disconnected for rat neck is put to death, isolate prostata tissue, shred, add the ratio mixing of normal saline 400 μ L in every 100mg prostata tissue。Draw 20 μ L suspensions, add numeration of leukocyte liquid 0.38mL, mixing, fill pond, cell counting count board counts the total white blood cells in the block plaid of 4, corner。TNF-α, IL-8 expression in ELISA kit detection rat blood serum and prostata tissue homogenate。
The ordinary circumstance of rat is observed in administration after terminating, model control group compares by rat with rats in sham-operated group, and movable minimizing, hypotrichosis is matt；Group rat is compared with model control group rat in treatment, and hair is relatively glossy, and ordinary circumstance still may be used。In modeling process, treatment group is died unexpectedly 1, dead 2 of model control group。
It addition, TNF-α and IL-8 level statistic result are in Table 1 in each group rat prostate tissue。By the result of the test of table 1 it can be seen that compared with sham operated rats, in model control group rat prostate tissue TNF-α and IL-8 level increase (P< 0.01)。Compared with model control group, treatment group rat TNF-α and IL-8 level significantly reduce (P< 0.01)。
Table 1 is respectively organized TNF-α and IL-8 level in rat prostate tissue and is compared
| Group | Sample size | TNF-α (ng/L) | IL-8(ng/L) |
| Sham operated rats | 20 | 3.71±0.46 | 24.15±2.94 |
| Model control group | 18 | 149.28±1.02★★ | 98.20±17.33★★ |
| Treatment group | 19 | 12.40±1.69▼▼ | 37.09±5.18▼▼ |
Model control group compares with sham operated rats,★ P< 0.05；★★ P< 0.01；Treatment group compares with model control group,▼ P< 0.05,▼▼ P< 0.01。
Each group rat leukocyte counting statistics result is in Table 2。By the test statistics result of table 2 it can be seen that sham operated rats is significantly lower than other two groups；The quantity of leucocyte for the treatment of group is remarkably decreased, compare with model control group have significant difference (P< 0.01)。
Rat leukocyte respectively organized by table 2 and Blood phospholipid corpusculum number compares
| Group | Sample size | Leukocyte (109Individual) |
| Sham operated rats | 20 | 1.80±0.21 |
| Model control group | 18 | 9.49±1.13★★ |
| Treatment group | 19 | 4.37±0.66▼▼ |
Model control group compares with sham operated rats,★ P< 0.05；★★ P< 0.01；
Treatment group compares with model control group,▼ P< 0.05,▼▼ P< 0.01。
Claims (2)
1. prepare the method treating prostatitic Chinese medicine composition for one kind, it is characterised in that prepared by following processing step:
(1) the following traditional Chinese medicinal material raw materials cleaned up is weighed by weight: Radix Adenophorae 9-15 part, Semen Sinapis Albae 9-15 part, stone Semen Benincasae 17-24 part, sea Semen Cassiae 10-18 part, Radix Oenotherae erythrosepalae 20-30 part, leaf of Turpinia pomifera (Roxb) D O. 20-30 part, conyza blinii 9-15 part, Folium Salicis Babylonicae 6-10 part；
(2) above raw material is merged, pulverize, boiling twice, add water 10 times amount into medical material weight for the first time, decoct 2h, add water 8 times amount into medical material weight for the second time, decoct 1h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 it is evaporated at 65 DEG C of temperature, adding 95%v/v ethanol makes alcohol content reach 75%v/v, stirring, stand 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, dried object pulverized 80 mesh sieves, obtain clear paste powder；The basis of clear paste powder prepares this Chinese medicine composition。
2. prepare the method treating prostatitic Chinese medicine composition according to claim 1, it is characterised in that: described Chinese medicine composition is oral formulations, and described oral formulations is oral liquid, granule, tablet or capsule。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610149899.2A CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610149899.2A CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410461218.7A Division CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105687438A true CN105687438A (en) | 2016-06-22 |
Family
ID=51955071
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610149899.2A Withdrawn CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
| CN201610145713.6A Withdrawn CN105582134A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610020122.6A Withdrawn CN105412320A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145713.6A Withdrawn CN105582134A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610020122.6A Withdrawn CN105412320A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (10) | CN105582133A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434982A (en) * | 2015-12-22 | 2016-03-30 | 青岛市市立医院 | Chronic nonbacterial prostatitis treating pharmaceutical composition |
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695555B (en) * | 2008-11-13 | 2011-05-18 | 赵子山 | Medicament composition for treating prostatitis and prostatomegaly and preparation method thereof |
| CN102379965A (en) * | 2011-08-14 | 2012-03-21 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating chronic prostatitis |
-
2014
- 2014-09-12 CN CN201610145710.2A patent/CN105582133A/en not_active Withdrawn
- 2014-09-12 CN CN201610149899.2A patent/CN105687438A/en not_active Withdrawn
- 2014-09-12 CN CN201610145713.6A patent/CN105582134A/en not_active Withdrawn
- 2014-09-12 CN CN201610020122.6A patent/CN105412320A/en not_active Withdrawn
- 2014-09-12 CN CN201610020124.5A patent/CN105412321A/en not_active Withdrawn
- 2014-09-12 CN CN201610145694.7A patent/CN105687437A/en not_active Withdrawn
- 2014-09-12 CN CN201610150077.6A patent/CN105582136A/en not_active Withdrawn
- 2014-09-12 CN CN201610149975.XA patent/CN105582135A/en not_active Withdrawn
- 2014-09-12 CN CN201610149971.1A patent/CN105535215A/en not_active Withdrawn
- 2014-09-12 CN CN201410461218.7A patent/CN104173547A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105582134A (en) | 2016-05-18 |
| CN105582135A (en) | 2016-05-18 |
| CN104173547A (en) | 2014-12-03 |
| CN105412320A (en) | 2016-03-23 |
| CN105687437A (en) | 2016-06-22 |
| CN105582133A (en) | 2016-05-18 |
| CN105535215A (en) | 2016-05-04 |
| CN105582136A (en) | 2016-05-18 |
| CN105412321A (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN105687438A (en) | Method for preparing traditional Chinese medicine composition for treating prostatitis | |
| CN1634319A (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN102085310A (en) | Medical composition for treating chronic pharyngitis | |
| CN113797298A (en) | Traditional Chinese medicine preparation for chronic hepatitis, preparation method and taking method thereof | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN106902306B (en) | Traditional Chinese medicine for treating kidney deficiency and blood stasis type benign prostatic hyperplasia bladder detrusor dysfunction and preparation method thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN103977276A (en) | Traditional Chinese medicine capsule used for treating radiocystitis | |
| CN114949108B (en) | Traditional Chinese medicine composition for treating prostatitis and preparation method and application thereof | |
| CN105663380A (en) | Method for preparing traditional Chinese medicine composition for treating prostatitis | |
| CN105663381A (en) | Application of Chinese herb extract to preparation of drug for treating prostatitis | |
| CN105770515A (en) | Traditional Chinese medicinal composition for treating prostatitis and preparation method of traditional Chinese medicinal composition | |
| CN105412679A (en) | Traditional Chinese medicine preparation for treating lung abscess and preparation method thereof | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN104958704A (en) | Pharmaceutical composition for treating bovine endometritis and preparation method of pharmaceutical composition | |
| CN104815131A (en) | Pharmaceutical composition for treating chicken gout and preparation method thereof | |
| CN112641908A (en) | Composition for treating gouty arthritis and preparation method thereof | |
| CN116115726A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux cough and application thereof | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof | |
| CN100411644C (en) | Medicine for treating chronic pharyngitis | |
| CN104096065A (en) | Traditional Chinese medicine composition for treating non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160622 |
|
| WW01 | Invention patent application withdrawn after publication |